Acorda Therapeutics, Inc.: 10-Q filed 2012-08-08

Name: Acorda Therapeutics, Inc.: 10-Q filed 2012-08-08
Creator: Acorda Therapeutics, Inc.

What Acorda Therapeutics, Inc. reported in its quarterly report filed 2012-08-08 (fiscal Q2 2012): 33 published measures, 96 facts as tagged in accession 0001008848-12-000044.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-08-08
Fiscal period: fiscal Q2 2012
Accession: 0001008848-12-000044 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Acorda Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-06-30	403,053,000	USD
At 2011-12-31	379,488,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-06-30	229,650,000	USD
At 2011-12-31	205,209,000	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-06-30	64,717,000	USD
At 2011-12-31	57,954,000	USD
At 2011-06-30	48,635,000	USD
At 2010-12-31	34,641,000	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	4,545,000	USD	91
2012-01-01 to 2012-06-30	12,391,000	USD	182
2011-04-01 to 2011-06-30	-285,000	USD	91
2011-01-01 to 2011-06-30	-957,000	USD	181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	6,418,000	USD	182
2011-01-01 to 2011-06-30	1,081,000	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-06-30	-397,090,000	USD
At 2011-12-31	-409,481,000	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	39,433,000	shares	91
2012-01-01 to 2012-06-30	39,387,000	shares	182
2011-04-01 to 2011-06-30	38,937,000	shares	91
2011-01-01 to 2011-06-30	38,859,000	shares	181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	40,099,000	shares	91
2012-01-01 to 2012-06-30	40,253,000	shares	182
2011-04-01 to 2011-06-30	38,937,000	shares	91
2011-01-01 to 2011-06-30	38,859,000	shares	181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	0.12	USD/shares	91
2012-01-01 to 2012-06-30	0.31	USD/shares	182
2011-04-01 to 2011-06-30	-0.01	USD/shares	91
2011-01-01 to 2011-06-30	-0.02	USD/shares	181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	0.11	USD/shares	91
2012-01-01 to 2012-06-30	0.31	USD/shares	182
2011-04-01 to 2011-06-30	-0.01	USD/shares	91
2011-01-01 to 2011-06-30	-0.02	USD/shares	181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	280,000	USD	91
2012-01-01 to 2012-06-30	652,000	USD	182
2011-04-01 to 2011-06-30	62,000	USD	91
2011-01-01 to 2011-06-30	179,000	USD	181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-06-30	14,290,000	USD
At 2011-12-31	3,858,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	9,784,000	USD	182
2011-01-01 to 2011-06-30	8,791,000	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	5,058,000	USD	91
2012-01-01 to 2012-06-30	13,913,000	USD	182
2011-04-01 to 2011-06-30	920,000	USD	91
2011-01-01 to 2011-06-30	1,361,000	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-06-30	327,237,000	USD
At 2011-12-31	360,942,000	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	356,000	USD	91
2012-01-01 to 2012-06-30	1,122,000	USD	182
2011-04-01 to 2011-06-30	1,276,000	USD	91
2011-01-01 to 2011-06-30	2,412,000	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-06-30	88,433,000	USD
At 2011-12-31	87,343,000	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-06-30	19,721,000	USD
At 2011-12-31	21,393,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2012-06-30	23,607,000	USD
At 2011-12-31	22,828,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	70,598,000	USD	91
2012-01-01 to 2012-06-30	132,991,000	USD	182
2011-04-01 to 2011-06-30	64,356,000	USD	91
2011-01-01 to 2011-06-30	125,201,000	USD	181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	44,230,000	USD	91
2012-01-01 to 2012-06-30	82,975,000	USD	182
2011-04-01 to 2011-06-30	40,141,000	USD	91
2011-01-01 to 2011-06-30	78,070,000	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	12,634,000	USD	91
2012-01-01 to 2012-06-30	23,659,000	USD	182
2011-04-01 to 2011-06-30	12,008,000	USD	91
2011-01-01 to 2011-06-30	22,716,000	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-06-30	39,467,153	shares
At 2011-12-31	39,328,495	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2012-06-30	-39,000	USD
At 2011-12-31	66,000	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2012-06-30	8,755,000	USD
At 2011-12-31	8,769,000	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2012-06-30	528,000	USD
At 2011-12-31	477,000	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2012-06-30	5,543,000	USD
At 2011-12-31	1,036,000	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2012-06-30	28,205,000	USD
At 2011-12-31	24,149,000	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	4,540,000	USD	91
2012-01-01 to 2012-06-30	12,286,000	USD	182
2011-04-01 to 2011-06-30	-213,000	USD	91
2011-01-01 to 2011-06-30	-833,000	USD	181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	4,545,000	USD	91
2012-01-01 to 2012-06-30	12,391,000	USD	182
2011-04-01 to 2011-06-30	-285,000	USD	91
2011-01-01 to 2011-06-30	-957,000	USD	181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	1,952,000	USD	182
2011-01-01 to 2011-06-30	2,175,000	USD	181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-233,000	USD	91
2012-01-01 to 2012-06-30	-870,000	USD	182
2011-04-01 to 2011-06-30	-1,143,000	USD	91
2011-01-01 to 2011-06-30	-2,139,000	USD	181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2012-01-01 to 2012-06-30	779,000	USD	182
2011-01-01 to 2011-06-30	1,145,000	USD	181

Inspect the source

Entity: Acorda Therapeutics, Inc. / CIK 0001008848
Captured: 2026-09-22 19:37 UTC
SEC response SHA-256: c2d58bfc837ef6a6ec03ace43e8d0507ad0968fa8666de37eb863e1308c9b0d4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001008848.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))